[{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"7d8868d0-7506-42fd-b3db-474559dd352d","acronym":"19-C-0116","url":"https://clinicaltrials.gov/study/NCT04002947","created_at":"2021-01-18T19:40:23.873Z","updated_at":"2025-02-25T13:39:52.977Z","phase":"Phase 2","brief_title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04002947 - 19-C-0116","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-21"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"796304d3-46d7-4eb0-aa64-9c9bbe7b7955","acronym":"Pola-R-ICE","url":"https://clinicaltrials.gov/study/NCT04833114","created_at":"2021-04-06T11:55:24.930Z","updated_at":"2025-02-25T14:15:54.989Z","phase":"Phase 3","brief_title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04833114 - Pola-R-ICE","lead_sponsor":"GWT-TUD GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"ad11f149-0ac3-4e5e-9a2c-090277fc61cc","acronym":"CRC-403","url":"https://clinicaltrials.gov/study/NCT05169489","created_at":"2021-12-27T15:54:15.732Z","updated_at":"2025-02-25T17:01:36.333Z","phase":"Phase 1/2","brief_title":"A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT05169489 - CRC-403","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bbT369"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-03"},{"id":"62643025-1b9c-4a89-a9ab-1626e60edfc3","acronym":"MPCT-012L","url":"https://clinicaltrials.gov/study/NCT05826535","created_at":"2023-04-24T14:04:02.070Z","updated_at":"2025-02-25T14:52:30.983Z","phase":"Phase 1/2","brief_title":"Study of IMPT-314 in R/R Aggressive B-cell NHL","source_id_and_acronym":"NCT05826535 - MPCT-012L","lead_sponsor":"ImmPACT Bio","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rondecabtagene autoleucel (LYL314)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-14"},{"id":"b7bc4ff3-bac9-4849-9ac4-4b756ff3134c","acronym":"ZUMA-24","url":"https://clinicaltrials.gov/study/NCT05459571","created_at":"2022-07-15T16:05:23.458Z","updated_at":"2024-07-02T16:34:25.986Z","phase":"Phase 2","brief_title":"Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05459571 - ZUMA-24","lead_sponsor":"Kite, A Gilead Company","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-14"},{"id":"597f3d3b-7b1b-4903-87c4-f3117fd83b5e","acronym":"topMIND","url":"https://clinicaltrials.gov/study/NCT04809467","created_at":"2021-03-22T11:52:17.035Z","updated_at":"2024-07-02T16:34:37.699Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT04809467 - topMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-06"},{"id":"ef515d3d-d584-4ab7-90a2-1415e247bfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04442022","created_at":"2021-01-18T21:22:49.510Z","updated_at":"2024-07-02T16:34:38.119Z","phase":"Phase 2/3","brief_title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04442022","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 501","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-05"},{"id":"e6bd139e-7d5b-486d-888f-481618f10fed","acronym":"LONCA","url":"https://clinicaltrials.gov/study/NCT05270057","created_at":"2022-03-08T16:52:28.981Z","updated_at":"2024-07-02T16:34:59.173Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","source_id_and_acronym":"NCT05270057 - LONCA","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-04"},{"id":"fd1aa0c0-bae7-44e0-b6d3-6aaebbda9e73","acronym":"TAK-007-2001","url":"https://clinicaltrials.gov/study/NCT05020015","created_at":"2021-08-25T14:53:09.103Z","updated_at":"2025-02-26T06:48:42.647Z","phase":"Phase 2","brief_title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","source_id_and_acronym":"NCT05020015 - TAK-007-2001","lead_sponsor":"Takeda","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAK-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 10/14/2025","primary_completion_date":" 10/14/2025","study_txt":" Completion: 06/20/2030","study_completion_date":" 06/20/2030","last_update_posted":"2024-05-29"},{"id":"dd766908-e225-4f48-b3e4-5c4320450a92","acronym":"LOTIS 5","url":"https://clinicaltrials.gov/study/NCT04384484","created_at":"2021-01-18T21:10:09.473Z","updated_at":"2024-07-02T16:35:00.891Z","phase":"Phase 3","brief_title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04384484 - LOTIS 5","lead_sponsor":"ADC Therapeutics S.A.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-05-27"},{"id":"679fafe7-f90a-4324-b109-03c540d1aab2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231747","created_at":"2021-01-18T20:35:10.173Z","updated_at":"2024-07-02T16:35:02.622Z","phase":"Phase 1","brief_title":"A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04231747","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • zolacaptagene autoleucel (BMS-986353)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-05-20"},{"id":"d08b3f2e-b940-4c34-82e7-531cd52cc0cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401020","created_at":"2023-02-21T20:01:15.546Z","updated_at":"2024-07-02T16:35:03.034Z","phase":"Phase 1","brief_title":"First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","source_id_and_acronym":"NCT04401020","lead_sponsor":"Sanofi","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SAR442257"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 03/02/2024","primary_completion_date":" 03/02/2024","study_txt":" Completion: 08/14/2024","study_completion_date":" 08/14/2024","last_update_posted":"2024-05-17"},{"id":"363e96eb-5e3f-442c-b58a-38eaeb74e6d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684563","created_at":"2021-03-16T19:53:11.570Z","updated_at":"2024-07-02T16:35:04.117Z","phase":"Phase 1","brief_title":"huCART19-IL18 in NHL/CLL Patients","source_id_and_acronym":"NCT04684563","lead_sponsor":"University of Pennsylvania","biomarkers":" ALK • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19 • huCART19-IL18"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/06/2021","start_date":" 05/06/2021","primary_txt":" Primary completion: 05/01/2036","primary_completion_date":" 05/01/2036","study_txt":" Completion: 05/01/2036","study_completion_date":" 05/01/2036","last_update_posted":"2024-05-13"},{"id":"52d33ddf-12db-4781-8289-d23be5e18186","acronym":"CYTB323A12101","url":"https://clinicaltrials.gov/study/NCT03960840","created_at":"2021-01-18T19:29:26.737Z","updated_at":"2024-07-02T16:35:06.077Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL","source_id_and_acronym":"NCT03960840 - CYTB323A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-05-03"},{"id":"099b5bf4-7bd1-4b6b-9199-1c53110e04ad","acronym":"DALY 2-EU","url":"https://clinicaltrials.gov/study/NCT04844866","created_at":"2021-04-14T11:52:59.944Z","updated_at":"2024-07-02T16:35:06.971Z","phase":"Phase 2","brief_title":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","source_id_and_acronym":"NCT04844866 - DALY 2-EU","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-04-30"},{"id":"8dda46df-1947-4289-9d30-b835dca6e2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03870945","created_at":"2021-01-18T19:05:14.371Z","updated_at":"2024-07-02T16:35:06.813Z","phase":"Phase 1/2","brief_title":"Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)","source_id_and_acronym":"NCT03870945","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zamtocabtagene autoleucel (MB-CART2019.1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 12/17/2020","primary_completion_date":" 12/17/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-30"},{"id":"b73496d5-e698-47e5-b7a2-1ea85e0d187e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696784","created_at":"2021-01-18T18:07:07.182Z","updated_at":"2024-07-02T16:35:07.400Z","phase":"Phase 1","brief_title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","source_id_and_acronym":"NCT03696784","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-26"},{"id":"9c9271f5-1a7e-4c0e-a836-6adeffa127dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04223765","created_at":"2021-04-23T04:56:25.788Z","updated_at":"2024-07-02T16:35:08.115Z","phase":"Phase 1","brief_title":"Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","source_id_and_acronym":"NCT04223765","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2043","study_completion_date":" 03/22/2043","last_update_posted":"2024-04-23"}]